REVIEW ARTICLE Stroke prevention in asymptomatic carotid artery disease...
the medically-treated arms of randomized trials testing carotid endarterectomy. 11 The most likely explanation for the decline in stroke rates is an interval improvement in medical management, particularly the use of "statin" medications that have been proved to remarkably reduce stroke risk in patients with carotid artery atherosclerosis.
12 Consequently, the modest absolute benefit conferred by carotid endarterectomy documented by randomized trials conducted 20 years ago is likely to be even smaller for contemporary patients with ACS managed aggressively with blood pressure control, lipid lowering using statins, and antiplatelet therapy. In short, because of low ipsilateral stroke rates in contemporary patients with ACS, many have questioned the relevance of these earlier trials to current practice.
2-4,13 On the other hand, the complication rates associated with revascularization of ACS may also be declining. 14 ACS is a risk factor for covert/silent brain infarcts detected by computed tomography in under the age of 70 years.
7 Among a cohort of patients with manifest arterial disease or diabetes mellitus with a mean age of 58 years, the frequency of ACS of 50% or higher was 8%.
8 However, in many of these studies, screening with carotid artery ultrasonography was not confirmed by other imaging modalities, and false-positive results are likely to have inflated prevalence estimates for ACS (see "Population screening for asymptomatic carotid stenosis" below).
Risk of stroke and other vascular events associated with asymptomatic carotid stenosis Based on consistent evidence, the absolute rate of ipsilateral stroke is low in contemporary patients with ACS, averaging 1% per year or lower among unselected patients 3,4,9,10 and those with vascular disease.
8 Current stroke rates associated with ACS are consistently lower than those reported in the 1980s and 1990s (which averaged 2%-4% per year) and are lower than stroke rates reported in FIguRE Example of a cervical carotid artery plaque that caused a high-grade carotid artery stenosis removed by carotid endarterectomy (courtesy of Dr. Jacques Tittley, Hamilton, Canada)
Revascularization for asymptomatic carotid stenosis: current guidelines Despite the concern that carotid revascularization is of no substantial benefit for the majority of ACS patients who are treated with contemporary medical management, current guidelines endorse revascularization for many patients with ACS (TAbLE 2) . Although guidelines attempt to synthesize the best available management recommendations, they are not without limitations. 52,53 Guideline recommendations favoring revascularization of ACS have been criticized on the basis that revascularization does not make sense for ACS patients with an annual risk of ipsilateral stroke of 1% to 2% because of the inherent upfront risk of opening the carotid arteries.
11, 22 The most recent European Stroke Organisation guideline is perhaps the most cautious regarding revascularization: "There is uncertainty about the benefit of revascularization for asymptomatic carotid stenosis … there is not enough data to recommend [stenting] as an alternative to [carotid endarterectomy]." 46 Population screening for asymptomatic carotid stenosis There is a general agreement in the recent literature that population screening for ACS is not warranted. 2,42,51,54-56 Using optimistic estimates for the sensitivity (95%) and specificity (92%) of carotid ultrasonography, screening of 100 000 adults assuming a true prevalence of ACS of 1% would yield 940 true-positive results and 7920 false-positive results, or a positive predictive value of about 10%.
2 Of note, the positive predictive value of ultrasonography is much higher in patients presenting to clinicians with asymptomatic bruits or other clinical manifestations of atherosclerosis (eg, peripheral vascular disease, contralateral ischemic stroke). The U.S. Preventive Services Task Force has recently reaffirmed its recommendation against screening for ACS in the general adult population based on patients without a history of stroke 8,15,16 ; however, covert/silent infarcts are equally distributed ipsilaterally and contralaterally to the side of the ACS. 17 Patients with ACS also have a substantial frequency of coronary artery atherosclerosis: myocardial infarction is about half as frequent as stroke, while the risk of cardiovascular death exceeds that of stroke.
8,18 Aggressive medical management of ACS offers the additional benefit of prevention of coronary events. There are too few high-quality studies to determine whether ACS is an independent risk factor for cognitive dysfunction, 19 and the effect of revascularization on measures of cognition have been mixed. 20
Can patients with asymptomatic carotid stenosis at high risk for stroke be identified? The degree of stenosis alone is a relatively weak predictor of ipsilateral stroke and does not identify medically treated patients with carotid artery atherosclerosis who have sufficient absolute rates of ipsilateral stroke to justify revascularization. 21 It has been estimated that with contemporary medical management only about 10% of unselected patients with ACS could benefit from additional revascularization.
22 Can high-risk subgroups be identified? This critical issue has recently received considerable attention (TAbLE 1) . ACS patients with other clinical manifestations of atherosclerosis (ie, coronary artery disease, peripheral vascular disease) or previous stroke have higher stroke risks, but the absolute rates have not been well characterized. High-resolution magnetic resonance imaging has been promising for identification of "vulnerable plaques" associated with higher risk of stroke (TAbLE 1) . 36, 37, 41 However, many experts believe that there are as yet no externally validated, reliable indicators that can identify ACS patients at an increased risk of stroke. It appears unlikely that addition of revascularization to medical management will show worthwhile absolute benefits for ACS patients chosen for inclusion based only on the degree of stenosis. In our view, restricting inclusion to ACS patients who have additional stroke risk factors will be required for randomized trials to have "positive", clinically meaningful results. For example, atrial fibrillation is a more powerful risk factor for stroke than ACS, and recent large randomized the uncertain absolute benefits of revascularization with either endarterectomy or stenting if added to current medical management. -recommended as an option for >70% stenosis or ill-defined "high-risk" or "selected" patients by many guidelines -about 10% of patients with acute coronary syndrome estimated to benefit from revascularization -no generally accepted criteria to define those at high-risk -occasionally justified by strong patient preferences high-risk ACS patients, the management controversies surrounding ACS will continue. Alas, there is no end in sight.
42-44
trials testing antithrombotic therapies were restricted to atrial fibrillation patients with additional stroke risk factors. The inclusion of patients with ACS in future randomized trials assessing revascularization should not be based solely on the degree of stenosis. Including otherwise unselected patients with ACS will bias results toward negative trials owing to the inclusion of low-risk patients with little potential to benefit from any intervention. While subgroup analyses of high-risk participants included in these trials are likely to be undertaken, even if planned a priori, interpretation in the setting of negative overall trial results is problematic. We endorse the recommendation of Naylor et al.
11 that "It is, therefore, essential that any new . . . randomized trials in asymptomatic patients include analysis of one or more . . . imaging strategies" or other features (TAbLE 1) to identify the subgroups at high risk for stroke who will benefit substantially from revascularization. 44 Nevertheless, definitively negative comparisons of invasive versus noninvasive treatment of ACS could usefully impact management in parts of the world such as the United States where revascularization of ACS patients is widely undertaken. 11,22
Management of asymptomatic carotid stenosis in 2015 Carotid artery stenosis of any degree is a relatively weak predictor of ipsilateral stroke, and it is time to move beyond ACS to focus research on defining high-risk carotid plaques (with stenosis as only one component). It is clear that nonstenotic carotid artery plaques can be a source of brain ischemia. 33 Medical management of ACS should include smoking cessation, antiplatelet therapy, high-dose "statin" therapy, and optimizing blood pressure (TAbLE 3) . Educating and periodically reeducating of ACS patients about symptoms of transient ischemic attack and stroke is important. We occasionally obtain ultrasonography in patients with asymptomatic cervical bruits to demonstrate ACS to further motivate patients to stick with prevention strategies (especially the difficult challenge of cessation of tobacco smoking).
Enthusiasm for revascularization is driven in part by the worst nightmare of clinicians that their patient with known ACS who is being treated medically experiences disabling stroke and that they "should have done more." This faulty reasoning is rarely in the best interest of their patient, exposing the overwhelming majority (95%) of ACS patients to unnecessary procedures that are not without risk.
59,60 Revascularization is not the right thing to do for most ACS patients, and restraint is warranted 3,4,13,22,42,44,61 (although not everyone agrees).
62 Until high-risk subgroups of ACS patients receiving contemporary medical therapy who could benefit substantially from revascularization are reliably identified (or the much larger low-risk subgroups who cannot), and revascularization is shown to be beneficial in contemporary randomized trials in
